Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mismatch Repair Deficient Solid Malignant Tumor”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Testing effectiveness (Phase 2)Looking for participantsNCT04165772
What this trial is testing

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Who this might be right for
Rectal AdenocarcinomaClinical Stage: Stage II (T3-4, N-)Stage III (Any T, N+)+2 more
Memorial Sloan Kettering Cancer Center 200
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Testing effectiveness (Phase 2)Active Not RecruitingNCT05199272
What this trial is testing

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaEpithelial Ovarian Cancer+6 more
23andMe, Inc. 141
Testing effectiveness (Phase 2)Active Not RecruitingNCT03228667
What this trial is testing

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Carcinoma+10 more
ImmunityBio, Inc. 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT06710847
What this trial is testing

Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Who this might be right for
Neoplasms, ColorectalSolid TumorColon Cancer+2 more
GlaxoSmithKline 14
Early research (Phase 1)Looking for participantsNCT06004245
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsColorectal Cancer
Vividion Therapeutics, Inc. 280
Not applicableNot Yet RecruitingNCT07374809
What this trial is testing

IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER

Who this might be right for
Endometrial Carcinoma (EC)pMMRDMMR Cancer
European Institute of Oncology 50
Testing effectiveness (Phase 2)Looking for participantsNCT05483400
What this trial is testing

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Who this might be right for
Head and Neck NeoplasmsMSI-H CancerMelanoma
University Medical Center Groningen 97
Testing effectiveness (Phase 2)Looking for participantsNCT03935893
What this trial is testing

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Who this might be right for
Gastric CancerColorectal CancerPancreatic Cancer+7 more
Udai Kammula 240
Early research (Phase 1)WithdrawnNCT04500548
What this trial is testing

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch Syndrome+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT04439214
What this trial is testing

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 47
Testing effectiveness (Phase 2)WithdrawnNCT04001101
What this trial is testing

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Who this might be right for
Microsatellite Instability HighMismatch Repair DeficiencyColorectal Cancer
University of Colorado, Denver
Large-scale testing (Phase 3)Looking for participantsNCT05770102
What this trial is testing

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Who this might be right for
MalignancyMalignant NeoplasmLymphoproliferative Disorders+7 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Looking for participantsNCT06580574
What this trial is testing

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Who this might be right for
Gastric CancerColon CancerMSI-H+1 more
Peking University 38
Testing effectiveness (Phase 2)Looking for participantsNCT04114136
What this trial is testing

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Who this might be right for
MelanomaNSCLCHepatocellular Carcinoma+5 more
Dan Zandberg 72
Testing effectiveness (Phase 2)UnknownNCT04521075
What this trial is testing

A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC

Who this might be right for
Melanoma Stage IVUnresectable MelanomaNSCLC Stage IV
Ella Therapeutics Ltd 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT04969887
What this trial is testing

Combination Immunotherapy in Rare Cancers Under InvesTigation

Who this might be right for
Advanced Biliary Tract CancerNeuroendocrine TumorsFemale Reproductive System Neoplasm+1 more
Olivia Newton-John Cancer Research Institute 240
Testing effectiveness (Phase 2)UnknownNCT04291248
What this trial is testing

Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

Who this might be right for
MSI-H or dMMR Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 138
Testing effectiveness (Phase 2)Looking for participantsNCT06047379
What this trial is testing

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Who this might be right for
Diffuse Astrocytoma, IDH-MutantGlioblastoma, IDH-wildtypeBrain Metastases, Adult+18 more
Neonc Technologies, Inc. 134
Early research (Phase 1)Active Not RecruitingNCT03589339
What this trial is testing

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Who this might be right for
RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant Tumour+8 more
Nanobiotix 145
Load More Results